A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Recruiting · NCT07361562 · Registry updated 2026-09-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-04 | NCT07361562 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cogent Biosciences, Inc. | 7 |
15 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | United States | 36 |
| LSU Health Sciences Center School of Medicine | New Orleans | United States | 1 |
| Mayo Jacksonville | Jacksonville | United States | 1 |
| Mayo Rochester | Rochester | United States | 5 |
| Mayo Scottsdale | Scottsdale | United States | 1 |
| NEXT Oncology Texas | Austin | United States | 1 |
| NEXT Oncology Virginia | Fairfax | United States | 40 |
| Northwestern University | Chicago | United States | 727 |
| NYU Langone | New York | United States | 34 |
| START Midwest | Grand Rapids | United States | 79 |
| START Mountain Region | West Valley City | United States | 46 |
| START NY Long Island | Lake Success | United States | 1 |
| Tennessee Oncology | Nashville | United States | 77 |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | United States | 19 |
| Yale Cancer Center | New Haven | United States | 42 |